FDA panel supports approval of Boehringer's olodaterol for COPD

An FDA advisory panel endorsed the approval of Boehringer Ingelheim's olodaterol as a once-daily bronchodilator treatment for chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Boehringer plans to market the drug in a soft mist inhaler under the name Striverdi Respimat.

View Full Article in:

Bloomberg Businessweek · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ